Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 5
1993 10
1994 10
1995 16
1996 14
1997 12
1998 16
1999 16
2000 15
2001 18
2002 42
2003 46
2004 68
2005 68
2006 76
2007 82
2008 92
2009 85
2010 118
2011 110
2012 109
2013 120
2014 133
2015 150
2016 133
2017 125
2018 95
2019 90
2020 97
2021 104
2022 76
2023 88
2024 77
2025 77
2026 53

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,180 results

Results by year

Filters applied: . Clear all
Page 1
Bivalirudin.
Berlioz BE, Patel P, Sanghavi DK. Berlioz BE, et al. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 32491755 Free Books & Documents.
This comprehensive activity delves into the nuanced aspects of bivalirudin therapy, shedding light on its indications, action, and contraindications. Beyond bivalirudin's established role in PCI, this session explores the broader applications of bivalirudi …
This comprehensive activity delves into the nuanced aspects of bivalirudin therapy, shedding light on its indications, action, and co …
Bivalirudin.
Warkentin TE, Greinacher A, Koster A. Warkentin TE, et al. Thromb Haemost. 2008 May;99(5):830-9. doi: 10.1160/TH07-10-0644. Thromb Haemost. 2008. PMID: 18449412 Review.
Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention (PCI). ...Besides summarizing the key trials evaluating bivalirudin use for acute coronary syn …
Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the setting of invasive cardiology, particula …
Bivalirudin: a review.
Warkentin TE, Koster A. Warkentin TE, et al. Expert Opin Pharmacother. 2005 Jul;6(8):1349-71. doi: 10.1517/14656566.6.8.1349. Expert Opin Pharmacother. 2005. PMID: 16013985 Review.
Bivalirudin (Angiomax) is a thrombin-inhibiting oligopeptide that was developed via rational drug design as a hirudin analogue ('hirulog'). ...It has certain pharmacological advantages over hirudin, including enzymic metabolism (less dependence on renal clearance) a …
Bivalirudin (Angiomax) is a thrombin-inhibiting oligopeptide that was developed via rational drug design as a hirudin analogue …
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L. McMichael A, et al. Pediatr Crit Care Med. 2025 Jan 1;26(1):e86-e94. doi: 10.1097/PCC.0000000000003642. Epub 2024 Nov 25. Pediatr Crit Care Med. 2025. PMID: 39585174 Free PMC article. Clinical Trial.
PATIENTS: Children 0 days to younger than 18 years old supported with ECMO in the PICU or cardiovascular ICU. INTERVENTIONS: Randomization to bivalirudin vs. unfractionated heparin while on ECMO. MEASUREMENTS AND MAIN RESULTS: Sixteen patients were randomized to bivalir …
PATIENTS: Children 0 days to younger than 18 years old supported with ECMO in the PICU or cardiovascular ICU. INTERVENTIONS: Randomization t …
Assays to Monitor Bivalirudin.
Davidson S. Davidson S. Methods Mol Biol. 2023;2663:369-380. doi: 10.1007/978-1-0716-3175-1_24. Methods Mol Biol. 2023. PMID: 37204724
Bivalirudin (Angiomax, Angiox) is a parenteral direct thrombin inhibitor (DTI) that is used for patients with heparin-induced thrombocytopenia (HIT), where heparin cannot be used due to the risk of thrombosis. Bivalirudin is also licensed for use in cardiolog …
Bivalirudin (Angiomax, Angiox) is a parenteral direct thrombin inhibitor (DTI) that is used for patients with heparin-induced …
Bivalirudin in Extracorporeal Membrane Oxygenation.
Dunham S, Wieruszewski PM, Gerrald JE. Dunham S, et al. J Cardiovasc Pharmacol. 2024 Dec 1;84(6):553-561. doi: 10.1097/FJC.0000000000001633. J Cardiovasc Pharmacol. 2024. PMID: 39259286 Review.
This review of the evidence for bivalirudin utilization in ECMO suggests favorable outcomes in circuit-related thrombosis, bleeding, and dosing reliability. ...Moreover, this review suggests that bivalirudin utilization presents the opportunity for ECMO management s …
This review of the evidence for bivalirudin utilization in ECMO suggests favorable outcomes in circuit-related thrombosis, bleeding, …
Bivalirudin in pediatric extracorporeal membrane oxygenation.
Ryerson LM, McMichael ABV. Ryerson LM, et al. Curr Opin Pediatr. 2022 Jun 1;34(3):255-260. doi: 10.1097/MOP.0000000000001131. Curr Opin Pediatr. 2022. PMID: 35634698 Review.
RECENT FINDINGS: Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, decreased cost and similar clinical outcomes for pediatric ECMO patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT i …
RECENT FINDINGS: Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, d …
Bivalirudin in acute coronary syndromes.
Galli M, Bernardi M, Ortega-Paz L, Nerla R, D'Amario D, Franchi F, Biondi-Zoccai G, Angiolillo DJ. Galli M, et al. Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(12):901-911. doi: 10.1080/14779072.2023.2273902. Epub 2023 Dec 13. Expert Rev Cardiovasc Ther. 2023. PMID: 37919937
INTRODUCTION: Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). ...However, RCTs on bivalirud …
INTRODUCTION: Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in throm …
Bivalirudin (Angiomax) for angioplasty.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2001 Apr 30;43(1103):37-8. Med Lett Drugs Ther. 2001. PMID: 11331441 No abstract available.
Bivalirudin: pharmacology and clinical applications.
Shammas NW. Shammas NW. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. doi: 10.1111/j.1527-3466.2005.tb00177.x. Cardiovasc Drug Rev. 2005. PMID: 16614733 Review.
Bivalirudin (Hirulog, Angiomax) is a specific, reversible and direct thrombin inhibitor with a predictable anticoagulant effect. ...ACT levels with bivalirudin do not correlate with its clinical efficacy. Bivalirudin with a provisional GpIIb/IIIa inhib …
Bivalirudin (Hirulog, Angiomax) is a specific, reversible and direct thrombin inhibitor with a predictable anticoagulant effec …
2,180 results